Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most citrus/grapefruit interaction statements are supported by the provided label (Section 7.2) and general muscle-risk linkage is consistent with the label’s skeletal muscle warnings; however, several specifics about oranges (including Seville oranges/bergamot, ingredient-dependent effects, and strength of oranges) are not supported by the provided label excerpts and are therefore partially unsupported.
Category Scores
Accurate Statements
Grapefruit can increase the level of some statins in the blood.
Section 7.2 Grapefruit Juice: contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Increasing statin blood levels can raise the risk of side effects such as muscle injury.
Section 5.1 Skeletal Muscle: rare rhabdomyolysis reported; warnings also state interacting drugs and increased risk context (provided excerpt indicates skeletal muscle risk and interaction-driven risk is addressed in later text).
The grapefruit interaction is typically due to inhibition of drug-metabolizing enzymes, commonly involving CYP3A4, in the gut.
Section 7.2: grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Inhibition of drug-metabolizing enzymes in the gut can make the statin stay in the body longer at higher concentrations.
Section 7.2 supports increased plasma concentrations from CYP3A4 inhibition; however, the provided excerpts do not specifically state 'stay in the body longer' or 'in the gut' for atorvastatin. (Marked accurate only insofar as CYP3A4 inhibition -> increased concentrations is supported.)
Symptoms suggesting a serious muscle reaction while on Lipitor include unexplained muscle pain, tenderness, weakness, or dark/tea-colored urine.
Section 5.1: rhabdomyolysis with acute renal failure secondary to myoglobinuria is reported; the excerpt supports serious muscle injury/myoglobinuria context, but the specific symptom list is not explicitly provided in the provided excerpts.
Unsupported Statements
There is no well-known specific interaction that requires avoiding oranges while taking Lipitor (atorvastatin).
The provided label excerpts specifically address grapefruit juice (Section 7.2) but do not state that oranges (whole oranges or orange juice) have no clinically relevant interaction; absence of label support in provided text.
Grapefruit (and sometimes Seville oranges/bergamot, depending on the product) is the citrus interaction most people commonly hear about with Lipitor.
The label excerpt does not mention Seville oranges or bergamot, nor does it support a 'most people commonly hear about' characterization.
Oranges are usually not in the same interaction category as grapefruit for Lipitor.
No orange-specific interaction categorization is provided in the provided label excerpts.
If an orange product contains grapefruit extract or is grapefruit-like in ingredients, it could change the interaction risk.
The label excerpt only addresses grapefruit juice consumption thresholds (Section 7.2) and does not support ingredient-dependent orange-product guidance.
Grapefruit is the best-known dietary trigger for this statin-enzyme interaction.
The label does not rank dietary triggers or use 'best-known' language.
Common oranges are generally not strong enough to cause the same effect as grapefruit.
No comparative strength of oranges vs grapefruit is provided in the label excerpts.
Orange juice may be treated differently depending on its components rather than whole fruit versus juice.
The label excerpts provided do not discuss orange juice components/processing differences.
If orange juice is clearly from oranges and not from grapefruit or a grapefruit-containing blend, it is usually not treated as a major interaction risk.
The label excerpts do not provide orange juice interaction risk guidance.
Contradictions
Low
AI Statement
There is no well-known specific interaction that requires avoiding oranges while taking Lipitor (atorvastatin).
Label Reference
No direct contradiction can be established from the provided label excerpts; grapefruit interaction is explicitly described, but oranges are not mentioned. Marked as unsupported rather than a contradiction.
Important Omissions
Grapefruit juice quantity/threshold detail: excessive grapefruit juice consumption (>1.2 liters per day).
Importance:
Moderate
Label-supported framing that grapefruit juice 'can increase plasma concentrations of atorvastatin' (without specifying 'in the gut' or duration mechanisms).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Grapefruit/CYP3A4 interaction risk is broadly supported; however, several orange-related claims could mislead readers about citrus interaction boundaries. Additionally, the label’s grapefruit juice consumption threshold is omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Orange/ingredient-dependent citrus interaction assertions are not supported by the provided FDA label excerpts, and the grapefruit juice consumption threshold (>1.2 liters/day) is omitted.
Suggested Improvement
Restrict interaction claims to what the label excerpt states: grapefruit juice components inhibit CYP3A4 and can increase atorvastatin concentrations, particularly with excessive consumption (>1.2 liters/day). Remove or qualify orange-specific statements unless supported by additional label text.